New nasal spray vaccine for RSV shows promise in young children

NCT ID NCT05687279

Completed ⭐️ VACCINE ⭐️ Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a live, weakened RSV vaccine given as a nasal spray to infants and toddlers aged 6 to 24 months in Puerto Rico. The main goal was to see if the vaccine virus spreads from vaccinated children to others in the same household or daycare, and to check how long the virus is shed. Researchers also looked at the vaccine's safety and how well it triggers an immune response. The study included 80 healthy children and compared the vaccine to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: live attenuated respiratory syncytial virus (RSV) vaccine given as a nasal spray
What this could lead to: If successful, this could lead to a safe RSV vaccine for infants that does not spread to others, helping protect young children from severe RSV disease.
What could go wrong: This is an early-phase study with only 80 participants, so results may not apply to larger populations. The vaccine virus might still spread or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTION

Contacts and locations

Locations

Investigational Site Number : 6300001

San Juan, 00918, Puerto Rico
Investigational Site Number : 6300002

Carolina, 984, Puerto Rico
Investigational Site Number : 6300003

Guayama, 00784, Puerto Rico
Investigational Site Number : 6300004

Bayamón, 00960, Puerto Rico
Meridian Clinical Research Norfolk Site Number : 8400003

Norfolk, Nebraska, 68701, United States
Velocity Clinical Research, Omaha Site Number : 8400001

Omaha, Nebraska, 68134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.